Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAN1012 in advanced solid tumors
NCT05580991Phase 1Active, not recruiting
- Sponsor
- Canwell Biotech Ltd.
- Start
- Sep 2022
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CAN1012 in solid tumor, sponsored by Canwell Biotech Ltd. Primary endpoints: Dose Limiting Toxicities at 12 months, Maximum Tolerated Dose at 12 months and 4 more. Started Sep 2022; status: active, not recruiting.
02
Drugs
CAN1012
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05580991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05580991.